

Tegobuvir Catalog No: tcsc0672

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Specifications

CAS No:

1000787-75-6

Formula:

 $C_{25}H_{14}F_7N_5$

Pathway:

Anti-infection

Target:

HCV

Purity / Grade:

Solubility: 10 mM in DMSO

Alternative Names: GS 333126;GS-9190

Observed Molecular Weight:

517.4


Product Description

Copyright 2021 Taiclone Biotech Corp.



Tegobuvir is a specific, covalent inhibitor of the **HCV NS5B polymerase**.

In Vitro: Tegobuvir rapidly increases the proportion of replicons with the Y448H mutation in a dose-dependent manner. After 3 days of treatment, 1.2%, 6.8%, and > 50% of the replicon population expresses Y448H with the use of Tegobuvir at 1, 10, and 20 times its 50% effective concentration, respectively^[1]. Tegobuvir exerts anti-HCV activity utilizing a unique chemical activation and subsequent direct interaction with the NS5B protein. Treatment of HCV subgenomic replicon cells with Tegobuvir results in a modified form of NS5B with a distinctly altered mobility on a SDS-PAGE gel^[2]. Tegobuvir is potent in GT1a and 1b with mean EC_{50} s of 19.8 and 1.5 nM respectively. For genotype 3a, 4a, and 6a Con chimeras, tegobuvir EC_{50} s are all greater than 100 nM. The F445C NS5B mutations in GT3a, 4a, and 6a chimeric replicons restore tegobuvir potency to EC_{50} levels comparable to GT1a^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.